This retrospective study used insurance claims data to examine the extent of twice-daily use of dornase alfa among cystic fibrosis patients. The study was done in partnership with researchers at Genentech, Inc. and presented at Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting in San Francisco. See the full poster here.
Five studies conducted by teams at PHAR were presented at the Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting in San Francisco. These studies cover a wide range of diseases and methods including cost effectiveness study of treatments for peripheral t-cell lymphoma, an analysis of insurance claims among cystic fibrosis patients, and an examination of patients with idiopathic pulmonary fibrosis using the National Inpatient Sample. The five posters can be found here.
A study conducted by the researchers at PHAR was selected for oral presentation at Endocrine Society’s 2016 Annual Meeting in Boston in April. The study used data from medical records at 8 US endocrine centers to describe treatment outcomes for Cushing’s Disease patients . The findings of the study can be viewed here. Including this one, there were 5 poster presentations of studies by PHAR. All posters presented at ENDO can be accessed here.
An abstract submitted by researchers at PHAR and Jazz Pharmaceuticals was highlighted by the American Society of Hematology (ASH) at their 57th Annual Meeting. The study estimated the total 100-day and one-year costs associated with inpatient hematopoietic stem cell transplantation, stratified by type of conditioning regimen and other potential contributors to cost. Researchers found that total per patient healthcare costs ranged from $182,000 to $409,000 in the one-year period post transplant. The poster can be accessed here.
For the second year in a row, PHAR was presented with a Silver Medal by the Academy of Managed Care Pharmacy. This year, the award was for a study on health care resource use and costs associated with high OCS use in patients with asthma, conducted by researchers at PHAR and Genentech, Inc., The retrospective claims analysis found that high OCS use was associated with significantly higher costs than no OCS use, especially in patients with possible side effects in the high OCS use cohort. The study can be viewed here.
Carcinoid syndrome describes the hormonal effects of carcinoid tumors, including the secretion of serotonin into the systemic circulation causing episodic diarrhea. Despite the frequent occurrence of this symptom, the healthcare costs and utilization associated with non-infectious diarrhea has not been elucidated. The researchers at PHAR and Novartis Pharmaceuticals Corporation presented their study on the economic impact of Non-Infectious Diarrhea in Patients with Carcinoid Syndrome at the 2015 North American Neuroendocrine Tumor Society’s Annual Symposium. They found that non-infectious diarrhea in newly-diagnosed carcinoid syndrome patients is associated with a significantly increased annual healthcare utilization and an additional $30,000 in total annual healthcare costs. The poster can be viewed here.
The Academy of Managed Care Pharmacy awarded its Silver Medal to a study conducted by PHAR and researchers from Novartis Pharmaceuticals Corporation. This retrospective claims analysis found that the per patient healthcare cost of Cushing’s disease care was more than double the cost for diabetes care and quadruple the cost for population-based controls. The study was presented at the AMCP Nexus Conference in Boston, MA. The poster can be viewed here.
A study completed by PHAR and researchers at bioTheranostics Inc found that use of bioTheranostics’ CancerTYPE ID® molecular test is a cost-effective approach to standardizing diagnostic methods for patients with metastatic tumors of uncertain origin while improving patient care. The study was the first of its kind to examine the implications of molecular classification in standardizing the diagnostic process for metastatic cancer. It was designed to estimate the clinical and economic tradeoffs of using CancerTYPE ID to aid in identifying the primary site of difficult-to-diagnose metastatic cancers and to explore whether the gene assay could be used to standardize the diagnostic process and costs for clinicians, payers, and patients. It was recently published in the Journal of Medical Economics and can be read here. The full press release can be accessed here.
PHAR announced that results from the first study to assess the clinical utility of the DCIS Score Assay in management of DCIS will be presented at American Society of Clinical Oncology (ASCO) Annual Meeting. Clinicians and breast cancer patients must decide among multiple treatment options including breast conserving surgery, mastectomy, partial or whole breast radiation, and hormonal manipulation. Treatment recommendations are usually made using clinicopathologic factors to estimate average local recurrence risk for similar patients. The validated Oncotype® DX 12-gene assay for DCIS gives additional, independent, individual estimates of 10-year risk In association with 10 cancer centers throughout the United States, PHAR conducted a prospective observation study on the impact of the DCIS Score result on radiation treatment recommendations for patients with DCIS. The study results will be presented at ASCO’s 50th Annual Meeting in Chicago, IL, and can be viewed here.
PHAR partnered with researchers at Genentech Inc. to study the relationship between the Healthcare Effectiveness Data and Information Set (HEDIS) and Asthma-Related Outcomes. Patients with low asthma medication ratio (AMR< 0.5) had worse asthma control by multiple measures including hospitalization/ED visits, OCS use, and SABA use. The number of asthma-related office visits was also slightly higher for low AMR patients. The findings support the use of AMR as a quality of care measurement for patients with persistent asthma. The Academy of Managed Care Pharmacy awarded this study a silver medal at their annual meeting. The poster presented at the AMCP Annual Meeting can be viewed here.